IFN-γ Identified as Promising Blood Biomarker for Alzheimer's Disease and Key Mechanistic Link

A recent study published in Frontiers in Immunology has identified interferon gamma (IFN-γ) as a significant blood-based biomarker for Alzheimer's disease (AD). The research further suggests that IFN-γ may serve as a crucial mechanistic link between genetic risk factors and inflammatory processes within the brain's microglia.

The Challenge of Alzheimer's Diagnosis

Alzheimer's disease, a progressive neurodegenerative disorder, presents a growing global challenge due to its increasing prevalence. Current diagnostic methods, including cognitive tests and advanced imaging techniques, are often costly and can be inaccessible to many.

While promising cerebrospinal fluid and blood-based biomarkers such as amyloid-β and phosphorylated Tau exist, their use is frequently limited to research settings. This highlights an urgent need for more accessible and widely available diagnostic tools for AD.

Microglia, Inflammation, and Genetic Risk in AD

Microglia, the immune cells of the central nervous system, are known to play a significant role in AD pathogenesis. Their activation by amyloid-beta plaques and neurofibrillary tangles initiates immune responses. Sustained microglial activation can lead to the production of neurotoxic mediators and the release of pro-inflammatory cytokines, thereby accelerating neurodegeneration.

The apolipoprotein E (APOE) ϵ4 allele is recognized as a major genetic risk factor for late-onset AD. It influences microglial function and is implicated in promoting detrimental neuroinflammatory cascades.

Study Design and Methodology

The study involved 141 participants, comprising individuals with Alzheimer's disease (AD), mild cognitive impairment (MCI), and healthy controls (HC). Researchers conducted a comprehensive array of assessments, including cognitive evaluations, MRI scans, and APOE genotyping. In addition, 16 plasma inflammatory biomarkers were analyzed using Luminex multiplex technology to identify potential indicators of AD.

Key Findings: Biomarker Identification and Diagnostic Potential

The investigation revealed several significant findings regarding inflammatory biomarkers in AD patients.
AD patients exhibited elevated levels of IFN-γ, IL-33, and IL-18, alongside decreased levels of IL-7, IL-6, and CCL11. Furthermore, higher levels of IFN-γ, IL-33, and IL-18 were found to correlate with poorer cognitive scores.

A predictive model, which incorporated clinical variables, APOE genotype, and plasma biomarkers, achieved a high accuracy (AUC = 0.953) in identifying AD. Notably, IFN-γ was the most significant contributor to this model.

IFN-γ alone demonstrated strong diagnostic potential, distinguishing AD from healthy controls (AUC = 0.913) and even from mild cognitive impairment (MCI) patients (AUC = 0.789).

IFN-γ, APOE ϵ4, and Microglial Mechanisms

Plasma IFN-γ levels were observed to be highest in AD patients who carry the APOE ϵ4 allele. Transcriptomic analyses of postmortem brain datasets further supported this connection, revealing heightened inflammatory and IFN-γ-related pathways in microglia from APOE4/4 AD patients. This was particularly evident in lipid droplet-accumulating microglia (LDAM), a harmful microglial subtype.

Experimental evidence from the study suggested that APOE 4 increased the expression of ACSL1, a known marker of LDAM. Intriguingly, IFN-γ further amplified this ACSL1 expression, especially in microglial cells that were overexpressing APOE 4. This indicates a potential interaction between IFN-γ and APOE 4, which could contribute to the promotion of detrimental microglial changes linked to AD pathology.

Conclusion and Future Outlook

The study positions IFN-γ as a promising biomarker for Alzheimer's disease, particularly in APOE ϵ4 carriers, and provides valuable insight into the interplay between genetic risk and immune signaling.

Elevated IFN-γ levels are associated with systemic inflammation and transcriptional signs of brain-specific inflammatory pathways. These pathways contribute to the expansion of harmful microglial subtypes through increased ACSL1 expression. This research lays a foundation for improved diagnostic strategies and potentially new therapeutic targets for AD. However, the findings require independent validation, and direct in vivo evidence linking peripheral IFN-γ to central microglial activation still needs to be established.